Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia

Apostolia Tsimberidou; Jorge Cortes; Deborah Thomas; Guillermo Garcia-Manero; Srdan Verstovsek; Stephan Faderl; Maher Albitar; Hagop Kantarjian; Elihu Estey; Francis J. Giles

doi:10.1016/S0145-2126(03)00022-5

Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia

Apostolia Tsimberidou, Jorge Cortes, Deborah Thomas, Guillermo Garcia-Manero, Srdan Verstovsek, Stephan Faderl, Maher Albitar, Hagop Kantarjian, Elihu Estey, Francis J. Giles

Research output: Contribution to journal › Article › peer-review

68 Scopus citations

Abstract

Clinical resistance to gemtuzumab ozogamicin (Mylotarg™) in acute myeloid leukemia (AML) is associated with blast multidrug resistance (MDR) phenotype. A Phase II study of Mylotarg, fludarabine, ara-C and the MDR-modifier, cyclosporine (CSA) (MFAC) was conducted in 32 patients with primary resistant (11, 34%) or relapsed (21, 66%) AML. Nine (28%) patients obtained complete remission (CR), two (6%) CR with incomplete platelet recovery. Overall median survival was 5.3 months, 12-month survival rate 19%. Fourteen patients (44%) developed grade 3/4 hyperbilirubinemia; six (18%) grade 3/4 hepatic transaminitis; three (9%) hepatic veno-occlusive disease (VOD). CSA inclusion in gemtuzumab ozogamicin-based regimens is feasible. MFAC is an effective regimen for refractory AML.

Original language	English (US)
Pages (from-to)	893-897
Number of pages	5
Journal	Leukemia Research
Volume	27
Issue number	10
DOIs	https://doi.org/10.1016/S0145-2126(03)00022-5
State	Published - Oct 1 2003
Externally published	Yes

Keywords

Acute myelogenous leukemia
Cyclosporine
Cytarabine
Fludarabine
Gemtuzumab ozogamicin
Mylotarg™
Refractory

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0145-2126(03)00022-5

Cite this

Tsimberidou, A., Cortes, J., Thomas, D., Garcia-Manero, G., Verstovsek, S., Faderl, S., Albitar, M., Kantarjian, H., Estey, E., & Giles, F. J. (2003). Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. Leukemia Research, 27(10), 893-897. https://doi.org/10.1016/S0145-2126(03)00022-5

Tsimberidou, A, Cortes, J, Thomas, D, Garcia-Manero, G, Verstovsek, S, Faderl, S, Albitar, M, Kantarjian, H, Estey, E & Giles, FJ 2003, 'Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia', Leukemia Research, vol. 27, no. 10, pp. 893-897. https://doi.org/10.1016/S0145-2126(03)00022-5

@article{552858823cf346779562b5f424cabacb,

title = "Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia",

abstract = "Clinical resistance to gemtuzumab ozogamicin (Mylotarg{\texttrademark}) in acute myeloid leukemia (AML) is associated with blast multidrug resistance (MDR) phenotype. A Phase II study of Mylotarg, fludarabine, ara-C and the MDR-modifier, cyclosporine (CSA) (MFAC) was conducted in 32 patients with primary resistant (11, 34%) or relapsed (21, 66%) AML. Nine (28%) patients obtained complete remission (CR), two (6%) CR with incomplete platelet recovery. Overall median survival was 5.3 months, 12-month survival rate 19%. Fourteen patients (44%) developed grade 3/4 hyperbilirubinemia; six (18%) grade 3/4 hepatic transaminitis; three (9%) hepatic veno-occlusive disease (VOD). CSA inclusion in gemtuzumab ozogamicin-based regimens is feasible. MFAC is an effective regimen for refractory AML.",

keywords = "Acute myelogenous leukemia, Cyclosporine, Cytarabine, Fludarabine, Gemtuzumab ozogamicin, Mylotarg{\texttrademark}, Refractory",

author = "Apostolia Tsimberidou and Jorge Cortes and Deborah Thomas and Guillermo Garcia-Manero and Srdan Verstovsek and Stephan Faderl and Maher Albitar and Hagop Kantarjian and Elihu Estey and Giles, {Francis J.}",

year = "2003",

month = oct,

day = "1",

doi = "10.1016/S0145-2126(03)00022-5",

language = "English (US)",

volume = "27",

pages = "893--897",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Limited",

number = "10",

}

TY - JOUR

T1 - Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia

AU - Tsimberidou, Apostolia

AU - Cortes, Jorge

AU - Thomas, Deborah

AU - Garcia-Manero, Guillermo

AU - Verstovsek, Srdan

AU - Faderl, Stephan

AU - Albitar, Maher

AU - Kantarjian, Hagop

AU - Estey, Elihu

AU - Giles, Francis J.

PY - 2003/10/1

Y1 - 2003/10/1

N2 - Clinical resistance to gemtuzumab ozogamicin (Mylotarg™) in acute myeloid leukemia (AML) is associated with blast multidrug resistance (MDR) phenotype. A Phase II study of Mylotarg, fludarabine, ara-C and the MDR-modifier, cyclosporine (CSA) (MFAC) was conducted in 32 patients with primary resistant (11, 34%) or relapsed (21, 66%) AML. Nine (28%) patients obtained complete remission (CR), two (6%) CR with incomplete platelet recovery. Overall median survival was 5.3 months, 12-month survival rate 19%. Fourteen patients (44%) developed grade 3/4 hyperbilirubinemia; six (18%) grade 3/4 hepatic transaminitis; three (9%) hepatic veno-occlusive disease (VOD). CSA inclusion in gemtuzumab ozogamicin-based regimens is feasible. MFAC is an effective regimen for refractory AML.

AB - Clinical resistance to gemtuzumab ozogamicin (Mylotarg™) in acute myeloid leukemia (AML) is associated with blast multidrug resistance (MDR) phenotype. A Phase II study of Mylotarg, fludarabine, ara-C and the MDR-modifier, cyclosporine (CSA) (MFAC) was conducted in 32 patients with primary resistant (11, 34%) or relapsed (21, 66%) AML. Nine (28%) patients obtained complete remission (CR), two (6%) CR with incomplete platelet recovery. Overall median survival was 5.3 months, 12-month survival rate 19%. Fourteen patients (44%) developed grade 3/4 hyperbilirubinemia; six (18%) grade 3/4 hepatic transaminitis; three (9%) hepatic veno-occlusive disease (VOD). CSA inclusion in gemtuzumab ozogamicin-based regimens is feasible. MFAC is an effective regimen for refractory AML.

KW - Acute myelogenous leukemia

KW - Cyclosporine

KW - Cytarabine

KW - Fludarabine

KW - Gemtuzumab ozogamicin

KW - Mylotarg™

KW - Refractory

UR - http://www.scopus.com/inward/record.url?scp=10744223798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744223798&partnerID=8YFLogxK

U2 - 10.1016/S0145-2126(03)00022-5

DO - 10.1016/S0145-2126(03)00022-5

M3 - Article

C2 - 12860008

AN - SCOPUS:10744223798

SN - 0145-2126

VL - 27

SP - 893

EP - 897

JO - Leukemia Research

JF - Leukemia Research

IS - 10

ER -

Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this